Navigation Links
Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses

The International Genomics Consortium’s (IGC) Expression Project for Oncology (expO) has released clinically annotated gene expression profiles for 60 tumor specimens, completing the initial phase of the nation’s first and eventually largest public database dedicated to standardized gene expression data. The clinically annotated dataset is available in the public domain through the National Center for Biotechnology Information web site at www.ncbi.nlm.nih.gov/geo/.

The goal of expO and its consortium supporters is to procure tissue samples under standard conditions and perform gene expression analyses on a clinically annotated set of deidentified tumor samples updated with clinical outcomes and release all data into the public domain without intellectual property restriction.

"This publicly accessible gene expression clinical database of patient specimens will fuel and accelerate clinically meaningful and scientifically valid research into better prognostic tests, new diagnostics, targeted therapies, predictive therapeutic strategies and potentially preventative modalities for patients" said IGC’s founder, Daniel Von Hoff, MD, FACP.

IGC has established a uniform system for obtaining and processing tissue samples for molecular characterization studies. Clinical annotation for each tissue sample will enable researchers to form testable clinical hypotheses for use in future treatment decision making. Tissue collection and data dissemination will be conducted in a manner that fully protects patient privacy. Over a three-year period, IGC expects to obtain 2,000 to 3,000 tumor specimens representing a broad spectrum of malignancies and 500-1,000 normal tissues.

expO has exceeded its first-year milestone of collecting consented and clinically annotated tumor biospecimens in a highly standardized format by 65%. This accomplishment puts expO on a projection to exceed its targeted collection and gene expression of 1,900 tumor biosamples over the course of 3 years.

Standardization of the collection, analysis, and vocabularies will help accelerate future development of new, targeted cancer treatments. Standardization, which will take place at every phase from consent to collection to gene expression, will result in better patient care.

Collaboration with the participating medical centers in the mechanics of tumor collection has also improved the quality of the collected tissues. The collection of tumor samples from surgery is historically difficult to achieve rapidly, due to the number of handling and review steps required to insure that the release of that tumor sample in no way jeopardizes patient care. Nonetheless, rapid handling is a necessity in order to maintain the integrity of RNA by quickly freezing the portion of tumor released for analysis. Historically, collection efforts typically achieve a successful preservation rate of 75%. Due to close collaboration between the surgeons, pathologists, local clinical research coordinators and expO, the success rate achieved in preserving these samples was 100%. Such well-preserved tissue allows the subsequent analysis to more precisely reflect the tumor’s biology.

"We are very pleased with the significant successes the project has achieved in our first year,"?said Robert Penny, M.D., Ph.D, Executive Director of expO and Chief Medical Officer of IGC. "These findings will be of benefit to the worldwide research community."

Consortium funding for expO’s launch comes from six international pharmaceutical firms. Major sponsors are Bristol-Myers Squibb, GlaxoSmithKline, Wyeth and IBM. Other sponsors are Pfizer, Aventis,

Johnson & Johnson, Flinn Foundation, ILEX Oncology, and Genomics Collaborative Inc. Research support from Affymetrix, AmeriPath, the Georgia Cancer Coalition, Agilent Technologies, Amersham Biosciences, and Telik Inc. also springboards the effort.

Major founding support was provided to IGC from Ari zona State University, the City of Phoenix, and from Maricopa County in Arizona.


'"/>

Source:International Genomics Consortium


Related biology news :

1. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
2. Iron Deficiency Sparks Dramatic Changes In Gene Expression
3. Applied Biosystems Introduces Advanced Gene Expression Service Provider Program
4. Gene Expression in the Aging Brain
5. The Shapes Of Life: NIGMS Project Yields More Than 1,000 Protein Structures
6. Whole genome promoter mapping - Human Genome Project v2.0?
7. Knockout Mouse Project
8. Worlds largest rainforest drying experiment completes first phase
9. Sandia completes depleted uranium study
10. LIAI completes worlds most comprehensive analysis on influenza virus data
11. A genes first kiss sets off that affair known as puberty
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December ... leading global financial services provider, today announced an agreement with ... behavioural biometrics, to join forces. The partnership will enable clients ... strategies in compliance with local data protection regulation. ... In order to ...
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
Breaking Biology News(10 mins):
(Date:1/18/2017)...  Caris Life Sciences, a leading innovator in ... private funder of pancreatic cancer research, are collaborating ... of immunotherapy in the treatment of pancreatic cancer. ... identify potential trial candidates based on biomarker expression ... study investigators. The Lustgarten Foundation is a sponsor ...
(Date:1/17/2017)... Foreside, Maine (PRWEB) , ... January 17, 2017 ... ... announce the addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration verification ... Rheumatoid Factor in a human serum base. Each VALIDATE® SP2 kit is prepared ...
(Date:1/17/2017)... Jan. 17, 2017  An international team of ... and St. Boniface Hospital Albrechtsen Research Centre/University of ... an unmet health need affecting nearly one in ... Clinical Investigation, their results identify small molecule drugs ... reverse neuronal injury in animal models of metabolic, ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
Breaking Biology Technology: